Physician profile
Yolanda Cherry Smith
NPI 1255791398
$2,661.68
in general payments reported to CMS, 2019-2025
14 companies · $63.13 in 2025
The $63.13 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $902 · 2023: $619 · 2024: $388 · 2025: $63.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $558.64 | 2021-2023 | Parsabiv, Tavneos |
| Astrazeneca Pharmaceuticals LP | $549.43 | 2021-2023 | Farxiga |
| Fresenius USA Marketing, INC. | $496.40 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Vifor Pharma, INC. | $315.40 | 2021-2024 | Veltassa |
| Calliditas Therapeutics US INC. | $211.42 | 2023 | Tarpeyo |
| Nxstage Medical, INC. | $169.76 | 2023 | Nxstage System One, Liberty Select Cycler |
| Aurinia Pharma U.S., INC. | $163.89 | 2022-2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.33 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $29.21 | 2024 | Ozempic |
| Glaxosmithkline, LLC. | $22.73 | 2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $21.88 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $21.00 | 2023 | Acthar |
| Akebia Therapeutics INC | $19.25 | 2022 | |
| Abbvie INC. | $18.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.